The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 16

PMID 33322239

Citations 9

Authors

Jessica McAnulty

Analisa DiFeo

Affiliations

Soon will be listed here.

Abstract

, a well-studied proto-oncogene that is overexpressed in >20% of tumors across all cancers, is classically known as "undruggable" due to its crucial roles in cell processes and its lack of a drug binding pocket. Four decades of research and creativity led to the discovery of a myriad of indirect (and now some direct!) therapeutic strategies targeting Myc. This review explores the various mechanisms in which Myc promotes cancer and highlights five key therapeutic approaches to disrupt Myc, including transcription, Myc-Max dimerization, protein stability, cell cycle regulation, and metabolism, in order to develop more specific Myc-directed therapies.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.

AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.

Oskouian B, Lee J, Asgharzadeh S, Khan R, Zhang M, Weisbrod J Oncogene. 2024; 43(16):1203-1213.

PMID: 38413795 PMC: 11014797. DOI: 10.1038/s41388-024-02980-y.

Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.

Murawski M, Jagodzinski A, Bielawska-Pohl A, Klimczak A Cells. 2024; 13(4.

PMID: 38391958 PMC: 10886918. DOI: 10.3390/cells13040345.

A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer.

Clusan L, Ferriere F, Flouriot G, Pakdel F Int J Mol Sci. 2023; 24(7).

PMID: 37047814 PMC: 10095386. DOI: 10.3390/ijms24076834.

Small molecule inhibitors for cancer metabolism: promising prospects to be explored.

Liu D, Wang H, Li X, Liu J, Zhang Y, Hu J J Cancer Res Clin Oncol. 2023; 149(10):8051-8076.

PMID: 37002510 DOI: 10.1007/s00432-022-04501-4.

References

Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W . c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1):68-79. PMC: 3471363. DOI: 10.1016/j.cell.2012.08.033. View

Zindy F, Eischen C, Randle D, Kamijo T, Cleveland J, Sherr C . Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998; 12(15):2424-33. PMC: 317045. DOI: 10.1101/gad.12.15.2424. View

Diaz R, Golbourn B, Faria C, Picard D, Shih D, Raynaud D . Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget. 2015; 6(5):3359-74. PMC: 4413659. DOI: 10.18632/oncotarget.3245. View

Kang J, Sergio C, Sutherland R, Musgrove E . Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014; 14:32. PMC: 3903446. DOI: 10.1186/1471-2407-14-32. View

Nau M, Brooks B, Battey J, Sausville E, Gazdar A, Kirsch I . L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985; 318(6041):69-73. DOI: 10.1038/318069a0. View

Bui T, Mendell J . Myc: Maestro of MicroRNAs. Genes Cancer. 2010; 1(6):568-575. PMC: 2946068. DOI: 10.1177/1947601910377491. View

Min S, Lau A, Lee T, Inuzuka H, Wei S, Huang P . Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell. 2012; 46(6):771-83. PMC: 3389221. DOI: 10.1016/j.molcel.2012.04.012. View

Amati B, Dalton S, Brooks M, Littlewood T, Evan G, Land H . Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992; 359(6394):423-6. DOI: 10.1038/359423a0. View

Shi C, Zhang H, Wang P, Wang K, Xu D, Wang H . PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis. Cell Death Dis. 2019; 10(11):815. PMC: 6814818. DOI: 10.1038/s41419-019-2022-2. View

10.

Boffo S, Damato A, Alfano L, Giordano A . CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018; 37(1):36. PMC: 5824552. DOI: 10.1186/s13046-018-0704-8. View

11.

Zhu X, Enomoto K, Zhao L, Zhu Y, Willingham M, Meltzer P . Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clin Cancer Res. 2016; 23(2):430-440. PMC: 5241246. DOI: 10.1158/1078-0432.CCR-16-0914. View

12.

Park S, Lin C, Ren N, Angus S, Dittmer D, Foote M . Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Target Oncol. 2019; 14(5):563-575. PMC: 6893856. DOI: 10.1007/s11523-019-00662-4. View

13.

Psathas J, Thomas-Tikhonenko A . MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med. 2014; 4(8). PMC: 4109576. DOI: 10.1101/cshperspect.a014175. View

14.

Alqahtani A, Choucair K, Ashraf M, Hammouda D, Alloghbi A, Khan T . Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019; 5(3):FSO372. PMC: 6426170. DOI: 10.4155/fsoa-2018-0115. View

15.

Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y . A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nat Commun. 2017; 8:15772. PMC: 5472749. DOI: 10.1038/ncomms15772. View

16.

Masso-Valles D, Soucek L . Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020; 9(4). PMC: 7226798. DOI: 10.3390/cells9040883. View

17.

Mita M, Joy A, Mita A, Sankhala K, Jou Y, Zhang D . Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer. 2014; 14(3):169-76. DOI: 10.1016/j.clbc.2013.10.016. View

18.

Yang Z, Yik J, Chen R, He N, Jang M, Ozato K . Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005; 19(4):535-45. DOI: 10.1016/j.molcel.2005.06.029. View

19.

Thomas L, Adams C, Wang J, Weissmiller A, Creighton J, Lorey S . Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proc Natl Acad Sci U S A. 2019; 116(50):25260-25268. PMC: 6911241. DOI: 10.1073/pnas.1910391116. View

20.

ONeil N, Bailey M, Hieter P . Synthetic lethality and cancer. Nat Rev Genet. 2017; 18(10):613-623. DOI: 10.1038/nrg.2017.47. View